Increased serum free IgE levels in patients with chronic spontaneous urticaria (CSU).

BACKGROUND

IgE bound on the surface of mast cells contributes to the pathogenesis of chronic spontaneous urticaria (CSU). Atopy is a predisposing factor for CSU, where omalizumab is a widely used monoclonal antibody to control urticaria symptoms via capturing serum free IgE. However, the role of serum free IgE is not clarified in CSU. The present study evaluated the clinical relevance of serum free IgE in patients with CSU.

METHODS

Eighty-eight patients with CSU and 76 healthy controls (HCs) were enrolled in this study. Serum total and ()-specific IgE levels were measured by ImmunoCAPs. The serum free IgE levels were measured by ELISA using a novel IgE, and their associations with clinical parameters, including urticaria activity score (UAS), were evaluated. Changes in serum free and total IgE levels after omalizumab treatment were observed in 23 CSU patients in comparison between responders (≥50% reduction in UAS) and non-responders (<50% reduction).

RESULTS

Significantly higher serum free/total IgE levels were noted in CSU patients than in HCs with a positive correlation between the 2 values ( = 0.87,  < 0.001). Among CSU patients, atopics had significantly higher serum free IgE levels than non-atopics, while no associations were noted with UAS, urticaria duration, or the results of serum ANA or autologous serum skin tests. In addition, there were no significant changes in serum free IgE levels during 12 months of omalizumab treatment. No significant differences were noted in serum free/total IgE levels or clinical parameters between responders and non-responders, while responders have higher serum -specific IgE level and its ratio to serum free/total IgE level than non-responders ( < 0.05, respectively).

CONCLUSIONS

These findings suggest that increased serum free IgE may be involved in the development of CSU by activating mast cells, especially in atopics. High specific IgE level and its ratio to serum free IgE level may be a potential biomarker for predicting favorable responses to omalizumab in CSU.